Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Mayne Pharma Group Ltd. operates as a specialized pharmaceutical enterprise, dedicated to the global production and distribution of both proprietary (branded) and unbranded (generic) medicinal products. Its extensive market reach spans Australia, New Zealand, North America (the United States and Canada), Europe, and Asia. The company's business activities are organized across four distinct divisions: Metrics Contract Services, International, Branded Products, and Portfolio Products. Mayne Pharma offers innovative oral drug delivery technologies and provides comprehensive contract services, including pharmaceutical development, manufacturing, and analytical support to external clients. Furthermore, the firm specializes in the distribution of pharmaceutical products tailored for key therapeutic areas such as dermatology, women's health, and infectious diseases. Incorporated in 2005, and headquartered in Salisbury South, Australia, the company was formerly known as Halcygen Pharmaceuticals Limited before rebranding to Mayne Pharma Group Limited in November 2010.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is of fair value on EV/EBITDA, trading at neutral level
Target Price
The average target price of MYX.AX is 5.41 and suggests 69.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in